CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00025259
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:36.655265+00:00
Published At: 2017-03-07T00:00:00+00:00
Record Updated At: 2017-04-12
Results Posted At: 2017-03-07
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma", "Childhood Mixed Cellularity Classical Hodgkin Lymphoma", "Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma", "Childhood Nodular Sclerosis Classical Hodgkin Lymphoma", "Stage I Childhood Hodgkin Lymphoma", "Stage II Childhood Hodgkin Lymphoma", "Stage III Childhood Hodgkin Lymphoma", "Stage IV Childhood Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-04-12"
protocolSection.identificationModule.nctId: "NCT00025259"
protocolSection.identificationModule.officialTitle: "A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-03-07"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.